Literature DB >> 21461617

Liquid chromatography-mass spectrometric determination of plasmalogens in human plasma.

Shu-Ping Hui1, Hitoshi Chiba, Takao Kurosawa.   

Abstract

A new liquid chromatography-mass spectrometry (LC/MS) method has been developed for the quantitative analysis of plasmalogens in human plasma using a nonendogenous plasmalogen (1-O-1'-(Z)-tricosenyl-2-oleoyl-rac-glycero-3-phosphocholine, PLS 23:0/18:1) as an internal standard. 1-O-1'-(Z)-Tricosenyl glyceryl ether was prepared by reacting lithioalkoxyallyl with 1-iodoeicosane as the key intermediate in the formation of PLS 23:0/18:1. In LC/MS analyses, PLS 23:0/18:1 generated significant fragment ions in positive and negative modes. In positive ion mode, the [M+H](+) of PLS 23:0/18:1 yielded unique fragments with cleavages at the sn-1 and sn-2 positions of the glycerol backbone. In negative ion mode, the [M+CH(3)COO](-) of PLS 23:0/18:1 resulted in characteristic fragmentation at the sn-2 and sn-3 positions. 1-O-1'-(Z)-Hexadecenyl-2-linoleoyl-rac-glycero-3-phosphocholine (PLS 16:0/18:2) and 2-arachidonoyl-O-1'-(Z)-hexadecenyl-rac-glycero-3-phosphocholine (PLS 16:0/20:4) were chemically synthesized as PLS 23:0/18:1. The calibration curves obtained for PLS 16:0/18:2 and PLS 16:0/20:4 were linear throughout the calibration range (0.04-1.60 pmol). The LOD (S/N = 5:1) was 0.008 pmol and the LOQ (S/N = 6:1) was 0.01 pmol for both PLS 16:0/18:2 and PLS 16:0/20:4. Plasma concentrations of PLS 16:0/18:2 and PLS 16:0/20:4 were 4.0 ± 1.3 μM and 3.5 ± 1.2 μM (mean ± SD), respectively, in five healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21461617     DOI: 10.1007/s00216-011-4921-7

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  8 in total

Review 1.  Lipidomic analysis of bacterial plasmalogens.

Authors:  Tomáš Řezanka; Zdena Křesinová; Irena Kolouchová; Karel Sigler
Journal:  Folia Microbiol (Praha)       Date:  2012-07-05       Impact factor: 2.099

2.  Serum choline plasmalogens, particularly those with oleic acid in sn-2, are associated with proatherogenic state.

Authors:  Megumi Nishimukai; Ryouta Maeba; Yuya Yamazaki; Toru Nezu; Toshihiro Sakurai; Yuji Takahashi; Shu-Ping Hui; Hitoshi Chiba; Tomoki Okazaki; Hiroshi Hara
Journal:  J Lipid Res       Date:  2014-03-10       Impact factor: 5.922

3.  Functional group selective derivatization and gas-phase fragmentation reactions of plasmalogen glycerophospholipids.

Authors:  Cassie J Fhaner; Sichang Liu; Xiao Zhou; Gavin E Reid
Journal:  Mass Spectrom (Tokyo)       Date:  2013-04-15

4.  Quantitative and Comparative Investigation of Plasmalogen Species in Daily Foodstuffs.

Authors:  Yue Wu; Zhen Chen; Jiaping Jia; Hitoshi Chiba; Shu-Ping Hui
Journal:  Foods       Date:  2021-01-08

5.  Laboratory diagnosis of disorders of peroxisomal biogenesis and function: a technical standard of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Irene De Biase; Silvia Tortorelli; Lisa Kratz; Steven J Steinberg; Kristina Cusmano-Ozog; Nancy Braverman
Journal:  Genet Med       Date:  2019-12-11       Impact factor: 8.822

6.  Measurement of Ether Phospholipids in Human Plasma with HPLC-ELSD and LC/ESI-MS After Hydrolysis of Plasma with Phospholipase A1.

Authors:  Shiro Mawatari; Seira Hazeyama; Takehiko Fujino
Journal:  Lipids       Date:  2016-07-07       Impact factor: 1.880

7.  Enzymatic measurement of ether phospholipids in human plasma after hydrolysis of plasma with phospholipase A1.

Authors:  Shiro Mawatari; Seira Hazeyama; Tomomi Morisaki; Takehiko Fujino
Journal:  Pract Lab Med       Date:  2018-01-09

8.  Alterations in the Plasma Levels of Specific Choline Phospholipids in Alzheimer's Disease Mimic Accelerated Aging.

Authors:  Fabian Dorninger; Ann B Moser; Jianqiu Kou; Christoph Wiesinger; Sonja Forss-Petter; Andreas Gleiss; Margareta Hinterberger; Susanne Jungwirth; Peter Fischer; Johannes Berger
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.